Annexon Inc (NAS:ANNX)
$ 5.39 0.05 (0.94%) Market Cap: 574.54 Mil Enterprise Value: 264.03 Mil PE Ratio: 0 PB Ratio: 1.72 GF Score: 40/100

Annexon Inc ARCHER Phase 2 Results at ASRS Call Transcript

Jul 31, 2023 / 08:30PM GMT
Release Date Price: $3.45 (+7.48%)
Operator

Hello, and welcome to Annexon's conference call. (Operator Instructions) Please be advised this call is being recorded at Annexon's request. I'd now like to turn the call over to Jen Lowe, Chief Financial Officer. You may begin.

Jen Lew
Annexon, Inc. - EVP & CFO

Thank you, and good afternoon. Yesterday, we issued a press release outlining results from our ARCHER Phase 2 clinical trial evaluating ANX007 in patients with geographic atrophy that were presented during an oral presentation at the ASRS 2023 Annual Meeting.

The press release, podium presentations and slides used for this conference call are available under the Events and Presentations page within the Investor section of our website.

Today's discussion will include forward-looking statements related to Annexon's current plans and expectations, which are subject to certain risks and uncertainties.

Actual results may differ materially due to various important factors, including those described in the Risk Factors section of our most recent Form 10Q and other SEC filings.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot